title: Evidence for the possible involvement of the P2Y(6) receptor in Ca (2+) mobilization and insulin secretion in mouse pancreatic islets.
abstract: Subtypes of purinergic receptors involved in modulation of cytoplasmic calcium ion concentration ([Ca(2+)](i)) and insulin release in mouse pancreatic beta-cells were examined in two systems, pancreatic islets in primary culture and beta-TC6 insulinoma cells. Both systems exhibited some physiological responses such as acetylcholine-stimulated [Ca(2+)](i) rise via cytoplasmic Ca(2+) mobilization. Addition of ATP, ADP, and 2-MeSADP (each 100 microM) transiently increased [Ca(2+)](i) in single islets cultured in the presence of 5.5 mM (normal) glucose. The potent P2Y(1) receptor agonist 2-MeSADP reduced insulin secretion significantly in islets cultured in the presence of high glucose (16.7 mM), whereas a slight stimulation occurred at 5.5 mM glucose. The selective P2Y(6) receptor agonist UDP (200 microM) transiently increased [Ca(2+)](i) and reduced insulin secretion at high glucose, whereas the P2Y(2/4) receptor agonist UTP and adenosine receptor agonist NECA were inactive. [Ca(2+)](i) transients induced by 2-MeSADP and UDP were antagonized by suramin (100 microM), U73122 (2 microM, PLC inhibitor), and 2-APB (10 or 30 microM, IP(3) receptor antagonist), but neither by staurosporine (1 microM, PKC inhibitor) nor depletion of extracellular Ca(2+). The effect of 2-MeSADP on [Ca(2+)](i) was also significantly inhibited by MRS2500, a P2Y(1) receptor antagonist. These results suggested that P2Y(1) and P2Y(6) receptor subtypes are involved in Ca(2+) mobilization from intracellular stores and insulin release in mouse islets. In beta-TC6 cells, ATP, ADP, 2-MeSADP, and UDP transiently elevated [Ca(2+)](i) and slightly decreased insulin secretion at normal glucose, while UTP and NECA were inactive. RT-PCR analysis detected mRNAs of P2Y(1) and P2Y(6), but not P2Y(2) and P2Y(4) receptors.
authors.affiliation: Research Institute of Pharmaceutical Sciences, Musashino University, 1-1-20 Shinmachi, Nishi-Tokyo, Tokyo, 202-8585, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ohtani
authors.forename: Jun-Ichiro
authors.initials: J
authors.lastname: Suzuki
authors.forename: Kenneth A
authors.initials: KA
authors.lastname: Jacobson
authors.forename: Takami
authors.initials: T
authors.lastname: Oka
references.citation: Am J Physiol Endocrinol Metab. 2004 May;286(5):E759-65
references.pmid: 14722025
references.citation: Eur J Pharmacol. 1988 Oct 11;155(1-2):171-4
references.pmid: 3072210
references.citation: Mol Pharmacol. 2002 Dec;62(6):1438-45
references.pmid: 12435812
references.citation: Mol Pharmacol. 2003 Oct;64(4):785-95
references.pmid: 14500734
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2002 Nov;366(5):464-9
references.pmid: 12382076
references.citation: Br J Pharmacol. 1989 Nov;98(3):875-82
references.pmid: 2686791
references.citation: Fundam Clin Pharmacol. 1997;11(6):537-45
references.pmid: 9444521
references.citation: Mol Pharmacol. 2006 Mar;69(3):899-907
references.pmid: 16332988
references.citation: Biochem Biophys Res Commun. 2008 Jun 6;370(3):499-503
references.pmid: 18387359
references.citation: J Med Chem. 2002 Sep 12;45(19):4057-93
references.pmid: 12213051
references.citation: Pharmacol Ther. 2006 Jun;110(3):415-32
references.pmid: 16257449
references.citation: Can J Physiol Pharmacol. 2002 Jun;80(6):562-8
references.pmid: 12117305
references.citation: Eur J Pharmacol. 1979 Nov 16;59(3-4):277-86
references.pmid: 393523
references.citation: Diabetes. 2005 Jul;54(7):2126-31
references.pmid: 15983214
references.citation: Br J Pharmacol. 1998 Nov;125(6):1368-74
references.pmid: 9863669
references.citation: Pancreas. 2001 Jan;22(1):69-71
references.pmid: 11138974
references.citation: Biochim Biophys Acta. 1988 Jun 30;970(2):222-9
references.pmid: 2454675
references.citation: Diabetes. 1999 Nov;48(11):2171-81
references.pmid: 10535451
references.citation: Cell Tissue Res. 2001 Dec;306(3):373-83
references.pmid: 11735037
references.citation: Eur J Pharmacol. 2007 Jul 30;568(1-3):54-60
references.pmid: 17509560
references.citation: Pharmacol Rev. 1998 Sep;50(3):413-92
references.pmid: 9755289
references.citation: Biochim Biophys Acta. 1992 Dec 11;1113(3-4):295-305
references.pmid: 1450203
references.citation: Proc Natl Acad Sci U S A. 1994 May 10;91(10):4343-7
references.pmid: 8183910
references.citation: Biochem Pharmacol. 1987 Feb 1;36(3):377-80
references.pmid: 3545218
references.citation: Biochem J. 1990 Jan 1;265(1):203-11
references.pmid: 2405836
references.citation: Biochem J. 1983 Feb 15;210(2):297-305
references.pmid: 6344863
references.citation: Diabetes. 1994 Dec;43(12):1413-7
references.pmid: 7958492
references.citation: Diabetes. 2001 Mar;50(3):540-50
references.pmid: 11246873
references.citation: Pharmacol Rev. 2003 Mar;55(1):105-31
references.pmid: 12615955
references.citation: Curr Top Med Chem. 2004;4(8):805-19
references.pmid: 15078212
references.citation: Purinergic Signal. 2005 Jun;1(2):145-51
references.pmid: 18404499
references.citation: Diabetes. 2004 Dec;53 Suppl 3:S63-6
references.pmid: 15561924
references.citation: Br J Pharmacol. 1991 Mar;102(3):627-30
references.pmid: 1364829
references.citation: Endocr Rev. 2001 Oct;22(5):565-604
references.pmid: 11588141
references.citation: J Biol Chem. 1991 Feb 25;266(6):3449-57
references.pmid: 1995609
references.citation: Biochem Pharmacol. 2000 May 15;59(10):1173-85
references.pmid: 10736418
references.citation: Mol Cell Endocrinol. 2003 Jun 30;204(1-2):141-54
references.pmid: 12850289
references.citation: Mol Cell Endocrinol. 2002 Jun 14;191(2):167-76
references.pmid: 12062900
references.citation: Biochim Biophys Acta. 1989 Jun 15;1012(1):107-15
references.pmid: 2543452
references.citation: Endocrine. 2003 Dec;22(3):185-92
references.pmid: 14709791